NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed 18h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPATCH is a transdermal estradiol/norethindrone acetate combination patch approved in 1998 for treating moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. It delivers both estrogen and progestin through the skin as an extended-release film formulation. The combination works via estrogen receptor agonism to alleviate menopausal symptoms while the progestin component protects the endometrium.
$5.0MPart D
LOE ApproachingThis product is approaching loss of exclusivity with modest Part D spending (~$5M) and modest claim volume (~11.5K), indicating a mature product with limited growth potential and likely stable or contracting team size.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Career Relevance
Career opportunities on COMBIPATCH are concentrated in quality assurance, manufacturing, and regulatory compliance rather than commercial or clinical expansion roles. Professionals joining this product team should expect stability in technical/operational functions but limited advancement pathways in brand development, given the approaching loss of exclusivity.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.